{
    "title": "Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin",
    "pmcid": "PMC11062152",
    "summary": "This study investigates risk factors for adverse events in patients with metastatic pancreatic cancer treated with nanoliposomal irinotecan combined with 5-fluorouracil and L-leucovorin (nal-IRI/FL). It specifically highlights the association of UGT1A1*6 or *28 polymorphisms with increased risks of leukopenia and neutropenia, with a significant incidence of low white blood cell and neutrophil counts observed in homozygous patients. Additionally, elevated aspartate aminotransferase (AST) levels prior to treatment and the location of tumors in the head of the pancreas were linked to further risk for leukopenia. The findings underscore the importance of monitoring genetic and clinical factors to manage treatment-related adverse effects.",
    "study_parameters": [
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": null,
            "Study Cases": 36,
            "Study Controls": null,
            "Characteristics": "Patients with metastatic pancreatic cancer; UGT1A1 genotypes (wild-type, heterozygous, homozygous)",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.033",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": null,
            "Study Cases": 36,
            "Study Controls": null,
            "Characteristics": "Patients with metastatic pancreatic cancer; UGT1A1 homozygous (+/+) genotype",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.009",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": null,
            "Study Cases": 36,
            "Study Controls": null,
            "Characteristics": "Patients with metastatic pancreatic cancer; high AST value before therapy",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.019",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": null,
            "Study Cases": 36,
            "Study Controls": null,
            "Characteristics": "Patients with metastatic pancreatic cancer; pancreatic head cancer",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.030",
            "Ratio Stat Type": "Unknown",
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": null,
            "Study Cases": 29,
            "Study Controls": null,
            "Characteristics": "Patients with metastatic pancreatic cancer; incidence of grade â‰¥1 diarrhea",
            "Characteristics Type": "Study Cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": null,
            "Ratio Stat Type": null,
            "Ratio Stat": null,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Unknown",
            "Variant Annotation ID_norm": null
        }
    ],
    "var_drug_ann": [
        {
            "Variant/Haplotypes": "UGT1A1*6 or *28 (+/+), UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
            "Gene": "UGT1A1",
            "Drug(s)": "nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Genotype of UGT1A1*6 or *28 (+/+) was significantly associated with decreased white blood cell count (p=0.009) and neutrophil count (p=0.017).",
            "Standardized Sentence": "Genotype *28/+ is associated with decreased leukopenia during nal-IRI/FL treatment in patients with metastatic pancreatic cancer.",
            "Alleles": "(+/+)",
            "Metabolizer types": "poor metabolizer",
            "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (+/-), UGT1A1*6 or *28 (-/-)",
            "Comparison Metabolizer types": "normal metabolizer",
            "Specialty Population": "",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Disease:metastatic pancreatic cancer",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": "counts of",
            "Multiple drugs And/or": "",
            "Multiple phenotypes or diseases And/or": "",
            "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
            ]
        }
    ],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "UGT1A1*6 or *28 (+/+), UGT1A1*6 or *28 (-/-), UGT1A1*6 or *28 (+/-)",
            "Gene": "UGT1A1",
            "Drug(s)": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
            "PMID": 38707740,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells and neutrophils.",
            "Sentence": "UGT1A1*6 or *28 (+/+) is associated with decreased white blood cell count and neutrophil count when treated with nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin in people with metastatic pancreatic cancer.",
            "Alleles": "(+/+), (-/-), (+/-)",
            "Specialty Population": null,
            "Metabolizer types": "poor metabolizer",
            "isPlural": "Are",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "likelihood of",
            "Phenotype": "leukopenia, neutropenia",
            "Multiple phenotypes And/or": "and",
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "metastatic pancreatic cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": "(-/-), (+/-)",
            "Comparison Metabolizer types": null,
            "PMID_norm": null,
            "Variant Annotation ID_norm": null,
            "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... and that of UGT1A1*6 or *28 (+/+) was significantly related to decreased neutrophil count (p=0.017).",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
            ]
        },
        {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "UGT1A1 polymorphism",
            "Gene": "UGT1A1",
            "Drug(s)": "Nanoliposomal irinotecan, 5-fluorouracil, L-leucovorin",
            "PMID": 38707740,
            "Phenotype Category": "dosage",
            "Significance": "yes",
            "Notes": "Decreased white blood cell count was significantly associated with high AST values before therapy and pancreatic head cancer.",
            "Sentence": "UGT1A1 polymorphism is associated with dosage requirements of nanoliposomal irinotecan when treated with 5-fluorouracil and L-leucovorin in people with metastatic pancreatic cancer.",
            "Alleles": null,
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": null,
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "dosage",
            "Phenotype": "dosage requirements",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": "and",
            "Population types": "in people with",
            "Population Phenotypes or diseases": "metastatic pancreatic cancer",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": null,
            "Variant Annotation ID_norm": null,
            "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)",
                "Patients with UGT1A1*6 or *28 (+/+) should be especially concerned about neutropenia and leukopenia during nal-IRI/FL treatment."
            ]
        }
    ],
    "var_fa_ann": [
        {
            "Variant/Haplotypes": "UGT1A1*6 or *28 (+/+)",
            "Gene": "UGT1A1",
            "Drug(s)": "Nanoliposomal irinotecan plus 5-fluorouracil and L-leucovorin",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043). Lower initial doses of nal-IRI were prescribed for these patients (median 48 mg/m^2).",
            "Sentence": "UGT1A1*6 or *28 (+/+) is associated with decreased white blood cell and neutrophil counts during nal-IRI/FL treatment as compared to UGT1A1*6 or *28 (-/-) and (+/-).",
            "Alleles": "(+/+)",
            "Metabolizer types": "/",
            "Comparison Allele(s) or Genotype(s)": "UGT1A1*6 or *28 (-/-) and (+/-)",
            "Assay type": "Statistical regression analysis",
            "Cell type": "Patient samples",
            "Specialty Population": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "Functional terms": "count of",
            "Gene/gene product": "UGT1A1",
            "When treated with/exposed to/when assayed with": "during nal-IRI/FL treatment",
            "Multiple drugs And/or": null,
            "Citations": [
                "Patients with UGT1A1*6 or *28 (+/+) exhibited significantly lower nadir counts of white blood cells (p=0.033) and neutrophils (p=0.043).",
                "Multiple regression analyses revealed that the decreased white blood cell count was significantly associated with the genotype of UGT1A1*6 or *28 (+/+) (p=0.009)... Also, the decreased neutrophil count was significantly related to the genotype of UGT1A1*6 or *28 (+/+) (p=0.017).",
                "The initial nal-IRI doses of patients with UGT1A1*6 or *28 (-/-), (+/-), and (+/+) were 56 (56-56), 56 (48-67), and 48 (40-49) mg/m^2 (median with the interquartile range), respectively. The prescribed nal-IRI doses for patients with UGT1A1*6 or *28 (+/+) were lower than those for other patients (p=0.011)."
            ]
        }
    ]
}